

Amendments to the Claims

Claims 1-16. (Cancelled)

17. (Previously Presented) A compound selected from the group consisting of:
4-{5-[(3-Methyl-butylamino)-methyl]-indol-1-ylmethyl}-benzamide,
4-{5-[(2-Thiophen-2-yl-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide,
4-{5-[(3,3-Dimethyl-butylamino)-methyl]-indol-1-ylmethyl}-benzamide,
4-{5-[(2-Thiophen-2-yl-ethylamino)-methyl]-2,3-dihydro-indol-1-ylmethyl}-benzamide,
4-{5-[(3-Methyl-butylamino)-methyl]-2,3-dihydro-indol-1-ylmethyl}-benzamide,
4-{5-[(3,3-Dimethyl-butylamino)-methyl]-2,3-dihydro-indol-1-ylmethyl}-benzamide,
4-(5-Hexylaminomethyl-indol-1-ylmethyl)-benzamide,
4-{5-[(3-Phenyl-propylamino)-methyl]-indol-1-ylmethyl}-benzamide,
4-(5-{[2-(2-Fluoro-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,
4-{5-[(2-Hydroxy-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide,
4-(5-{[2-(4-Methoxy-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,
4-{5-[(2-Chloro-6-fluoro-benzylamino)-methyl]-indol-1-ylmethyl}-benzamide,
4-{5-[(2-Pyridin-3-yl-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide,
4-(5-{[2-(2-Ethoxy-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,
4-(5-{[2-(Tetrahydro-pyran-4-yl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,
4-{5-[(2-Cyclohex-1-enyl)-ethylamino]-methyl}-indol-1-ylmethyl}-benzamide,
4-(5-{[2-(3-Fluoro-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,
4-{5-[(2-Ethyl-butylamino)-methyl]-indol-1-ylmethyl}-benzamide,
1-[4-[(3-Methyl-butylamino)-methyl]-benzyl]-2,3-dihydro-1H-indole-5-carboxylic acid
amide,
1-[4-[(3-Methyl-butylamino)-methyl]-benzyl]-1H-indole-5-carboxylic acid amide,
or a pharmaceutically acceptable salt or solvate thereof.

18. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)

26. (Cancelled)

27. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of ~~Claim 24~~Claim 17 in association with a carrier, diluent and/or excipient.